Published • loading... • Updated
Dompe to Pay $32 Million over Medicare Co-Pay Scheme for Eye Drug
Summary by The New York Ledger
4 Articles
4 Articles
Washington TimesReposted by 
The New York Ledger
The New York LedgerDompe to pay $32 million over Medicare co-pay scheme for eye drug
Dompe U.S. Inc., the American subsidiary of Italy-based Dompe farmaceutici S.p.A., has agreed to pay $32 million to resolve allegations that it violated the Anti-Kickback Statute and the False Claims Act, the Justice Department announced.
·Washington, United States
Read Full Article
Dompé u.s. agrees to pay $32m to resolve false claims act liability relating to self-disclosure of patient kickbacks
Inc. (Dompé), based in California, has agreed to pay $32 million to resolve allegations that, between 2018 and 2021, it paid Medicare beneficiary co-pays through two patient assistance foundations to induce the purchase of its drug, Oxervate, in violation of the Anti-Kickback Statute and the False Claims Act. “This settlement demonstrates the United States’ commitment […]
·Sheridan, United States
Read Full ArticleCoverage Details
Total News Sources4
Leaning Left0Leaning Right1Center1Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
